|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 恶性肿瘤骨转移及骨相关疾病临床诊疗中国专家共识(英文)显示文摘Since 1980s, palliative medicine has been an independent educational project. The development of palliative care in China started in the early 1990s. During the last 18 years, we have seen an increasing allocation of resources to palliative care, the establishment of an academic chair in palliative medicine, and more focused interest and awareness of the need for palliative care in the society at large. So the doctors in China have established principles of treatment on clinical diagnosis and treatment of malignant tumor bone metastases and bone related complications. In order to share our experience with the world, after two years’ preparation, the top-level experts in palliative medicine have written the consensus statement on clinical diagnosis and treatment of malignant tumor bone metastases and bone related complications. The overview includes not only the achievements in the world, but the hands-on experience in clinic, especially the experience in combination of TCM and Western medicine. We hope that the publication of this consensus statement will contribute to the palliative medicine development in this field, thus bring benefits to the majority of patients. | Shiying Yu Zefei Jiang Li Zhang Xiaohui Niu Lvhua Wang Ning Wu Jianhui Ma | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，1： | 15 |
| 2 | Exploratory clinical study of chidamide,an oral subtype-selective histone deacetylase inhibitor,in combination with exemestane in hormone receptor-positive advanced breast cancer显示文摘Objective: The recurrence or progression under endocrine therapy in hormone receptor-positive(HR+)advanced breast cancer(ABC) remained a critical clinical challenge.Chidamide is an oral subtype-selective histone deacetylase(HDAC) inhibitor with multiple functions in tumor growth inhibition and microenvironment modulation via epigenetic reprogramming.The purpose of this study was to evaluate the safety,pharmacokinetics(PK),and preliminary efficacy of chidamide in combination with exemestane in HR+ ABC patients.Methods: Eligible patients were postmenopausal women with HR+ ABC recurrent or progressed to at least one endocrine therapy.Blood samples were obtained in the run-in period and the first day of combination treatment for PK analysis.In combination treatment,patients were given exemestane 25mg daily and chidamide 30mg twice a week(BIW) until progression of disease or intolerable toxicities.A treatment cycle was defined as 4 weeks.Safety,PK parameters,and preliminary efficacy were evaluated.Results: A total of 20 patients were enrolled between July and December,2015.The median number of treatments cycle was 5.2(20.8 weeks) with 2 patients still on treatment at the data cut-off date of October,2017.The treatment-related adverse events(AE) ≥ grade 3 in more than 2 patients were neutropenia(35%),thrombocytopenia(30%),and leucopenia(20%).The plasma exposure of exemestane was consistent in the presence or absence of chidamide.A slight increase in chidamide exposure was noted in the presence of exemestane,probably due to the inter-and intra-patient variations.The best response in 16 evaluable patients was assessed by Response Evaluation Criteria in Solid Tumors(RECIST),including 4 patients with partial response,10 patients with stable disease.The median progression-free survival(PFS) was 7.6 months.Conclusions: The combination of chidamide with exemestane was generally well tolerated with promising preliminary efficacy in HR+ ABC patients.The overall results from this study encourage further pivotal trial in this patient population. | Qingyuan Zhang Tao Wang Cuizhi Geng Yue Zhang Jinwen Zhang Zhiqiang Ning Zefei Jiang | 2018 | Chinese Journal of Cancer Research2018，30，6： | 11 |
| 3 | Chinese Society of Clinical Oncology Breast Cancer(CSCO BC)guidelines in 2022:stratification and classification显示文摘In April 2017,the first edition Chinese Society of Clinical Oncology Breast Cancer(CSCO BC)guidelines were released.These guidelines were based on medical evidence,as well as the accessibility and cost effectiveness of various anticancer drugs in China.The CSCO BC guidelines include regimens with a high level of evidence,good product accessibility and high consistent consensus among Chinese experts as level I recommendations.Regimens with a high level of evidence but poor product accessibility or expert consensus are included as level II recommendations. | Jianbin Li Zefei Jiang | 2022 | Cancer Biology & Medicine2022，19，6： | 8 |
| 4 | LSECtin on tumor-associated macrophages enhances breast cancer sternness via interaction with its receptor BTN3A3显示文摘Macrophages have bee n suggested to con tribute to con structing a cancer stem cell(CSC)niche.However,whether and how macrophages regulate the activity of CSCs through juxtacrine signaling are poorly understood.Here we report LSECtin,a transmembrane protein highly expressed on tumor-associated macrophages(TAMs),enhances sternness of breast cancer cells(BCCs).We identified BTN3A3,a B7 family member with previously unknown functions as the receptor for LSECtin on BCCs responsible for stemness-promoting effect of LSECtin.In mice bearing human tumor xenografts,either macrophage-specific ablation of LSECtin or silencing of BTN3A3 in BCCs decreased CSC frequency and tumor growth.Admixture of LSECtin-positive macrophages increased the tumorigenic activity of BCCs dependent on BTN3A3.Disruption of the LSECtin-BTN3A3 axis with BTN3A3-Fc or anti-BTN3A3 mAb has a therapeutic effect on breast cancer.These findings define a juxtacrine signaling mechanism by which TAMs promote cancer stemness.Targeting this axis in the CSC niche may provide potential therapies to breast cancer. | Di Liu Qian Lu Xing Wang Jun Wang Ning Lu Zefei Jiang Xiaopeng Hao Jianbin Li Jing Liu Pengbo Cao Guilin Peng Yuandong Tao Dianyuan Zhao Fuchu He Li Tang | 2019 | Cell Research2019，29，5： | 8 |
| 5 | Multicenter prospective study of magnetic resonance imaging prior to breast-conserving surgery for breast cancer显示文摘 | Liu Qian Liu Yinhua Xu Ling Duan Xuening Li Ting Qin Naishan Kang Hua Jiang Hongchuan Yang Deqi Qu Xiang Jiang Zefei Yu Chengze | 2014 | Chinese Medical Journal2014，，13： | 6 |
| 6 | Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China:A pooled retrospective analysis of four observational studies显示文摘Objective:Adjuvant docetaxel-based chemotherapy is frequently used for operable early breast cancer(EBC).This study investigated patterns of use of docetaxel(T)in real-life clinical practice in China.Methods:This was a retrospective pooled analysis of the Asia-Pacific Breast Initiatives(APBI)Ⅰ(2006–2008)and Ⅱ(2009–2011)registries,and two Chinese observational studies;BC STATE(2011–2014)and BC Local Registry(2007–2010).Female Chinese adults(≥18 years)with operable breast cancer treated with docetaxel-based adjuvant chemotherapy were included in the analysis.Patients with metastatic disease were excluded.The primary endpoint was assessment of treatment patterns and patient profiles.A logistic regression analysis was conducted to identify factors associated with choice of adjuvant chemotherapy regimen.Results:Data from 3,020 patients were included.The most frequently used adjuvant regimen was docetaxel/anthracycline combination[n=1,421(47.1%);of whom 52.0%received T/epirubicin(E)/cyclophosphamide(C)],followed by docetaxel/other[n=705(23.3%);of whom 72.8%received TC],docetaxel/anthracycline sequential[n=447(14.8%);of whom 40.9%and 39.6%received 5-Fu/EC-T and EC-T,respectively],and'other'[n=447(14.8%);of whom 91.5%received T].A significant association was found between adjuvant therapy with docetaxel/anthracycline combination and patient weight,menopausal status and estrogen receptor status.Conclusions:Real-world data revealed that docetaxel/anthracycline combination is the most commonly used category of docetaxel-based adjuvant therapy for patients with operable breast cancer in China;of which TEC is the most frequently used regimen. | Binghe Xu Zhimin Shao Shui Wang Zefei Jiang Xichun Hu Xiaohua Zhang Xiru Li Jinping Liu Mengquan Li Shu Wang | 2018 | Chinese Journal of Cancer Research2018，30，3： | 5 |
| 7 | CSCO breast cancer guideline: precise, economical and oriental显示文摘Chinese Society of Clinical Oncology (CSCO) is a national non-profit academic organization formed by Chinese clinical oncologists, surgeons, radiation oncologists and researchers.Since its establishment in 1997, CSCO has become one of the most important clinical societies and one of the biggest platforms of continuing medical education in China. CSCO has now more than 28,000 members, and its annual meeting has more than 35,000 participants every year, making it one of the largest cancer conferences worldwide. | Qian Li Jieqiong Liu Zefei Jiang Qiang Liu | 2020 | Science China(Life Sciences)2020，63，9： | 3 |
| 8 | Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab:A real-world study显示文摘Objective:Several studies have demonstrated different benefits for patients whose disease progressed despite previous trastuzumab treatment.Due to limited real-world data,we evaluate the effectiveness of anti-human epidermal growth factor receptor 2(HER2)therapy(lapatinib or trastuzumab)plus chemotherapy or chemotherapy alone in patients who were previously treated with trastuzumab-containing regimens and investigate factors associated with effectiveness.And we further show the effectiveness of the two anti-HER2 therapy groups.Methods:A total of 342 HER2-positive metastatic breast cancer(MBC)patients whose disease progressed during prior anti-HER2(trastuzumab)and standard chemotherapy therapy from Department of Breast Oncology,the Fifth Medical Center of Chinese PLA General Hospital,from August 2010 to December 2016 were included.Seventy-eight patients received standard chemotherapy only,148 patients continued to receive trastuzumab and switched to other chemotherapy drugs,and 116 patients received tyrosine-kinase inhibitors(TKIs;lapatinib)and chemotherapy.The main outcome measures were progression-free survival(PFS),overall response rate(ORR),and clinical benefit rate(CBR).Subgroup analyses were conducted to identify patient characteristics associated with the greatest clinical benefit.Results:After a median follow-up of 26.2(range,2.0-56.0)months,PFS significantly improved with anti-HER2 therapy compared with chemotherapy alone:median 6.0 months with lapatinib[95%confidence interval(95%CI),4.53-7.47],4.5 months with trastuzumab(95%CI,3.99-5.01)vs.3.0 months with chemotherapy alone(95%CI,2.42-3.58);stratified hazard ratio(HR)=0.70,95%CI,0.60-0.81;P<0.0001.The ORR values were 33.6%,25.0%and 12.8%,respectively,the CBR values were 60.3%,48.6%and 26.9%,respectively.The effectiveness of lapatinib group and trastuzumab group were further analyzed.In multivariate analysis,lapatinib group was associated with a longer PFS,after controlling other potential confounders(HR=0.68,95%CI,0.52-0.90;P=0.006).Conclusions:The combination of TKIs and chemotherapy was effective in this cohort previously treated with trastuzumab treatment.Therefore,TKIs combined with chemotherapy is an option for Chinese HER2-positive MBC patients previously treated with trastuzumab treatment. | Wei Zhao Li Bian Tao Wang Shaohua Zhang Jianbin Li Fengrui Xu Zefei Jiang | 2020 | Chinese Journal of Cancer Research2020，32，3： | 1 |
| 9 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer显示文摘 | Hongyan Huang Zefei Jiang Tao Wang Shaohua Zhang Li Bian Yang Cao Shikai Wu Santai Song | 2012 | Anti-Cancer Drugs2012，，7： | 1 |
| 10 | Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer显示文摘 | Tao Wang Shaohua Zhang Min Zeng Xinyou Lu Ge Shen Shikai Wu Santai Song Zefei Jiang | 2012 | Medical Oncology2012，，1： | 1 |
| 11 | Improved Fatigue and Damage Tolerant Material Design for Aerospace Industry显示文摘Various micro-mechanical and micro-structural influences on fatigue crack growth resistance of the material havebeen investigated over the years. It is widely recognized that resistance to fatigue crack growth can be differentiatedinto ’intrinsic’ and ’extrinsic’. The separation of intrinsic and extrinsic crack growth resistance has constituted amajor theme of fatigue research in the last 30 years, with the concept of crack closure or crack tip shielding beingused to rationalize a wide range of micro-structural and mechanical influences on fatigue crack growth behavior. Anaccurately quantitative understanding of intrinsic and extrinsic effects on crack growth is essential to directed alloydesign for improved fatigue resistance, and/or improved structural service life. This paper presents a compliance-basedcrack closure measurement method and a multi-mechanism based analytical model for the separation of intrinsic andextrinsic material fatigue resistance, with application in characterizing the fatigue performance of two high strengthdamage tolerant airframe Al alloys. | Yigeng XU Jiang CHEN Jianmin LI Zefei ZHU | 2005 | Journal of Materials Science & Technology2005，21，6： | 1 |
| 12 | 原癌基因Fra-1在乳腺恶性肿瘤组织中的表达(英文)显示文摘Objective:Invasion and metastasis are the most significant and intrinsic biological characteristics of cancers,also which are main factors of malignant tumor causing treatment failure and death.Recent studies have found that Fra-1 plays an important role on cell migration,invasion,and maintaining malignant phenotype of transformed cells.But there are few studies about the expression and location of Fra-1 in breast tissues and cells being reported.This study just aims to discuss the expression and location of transcription factor Fra-1 in benign and malignant human breast tissues.Methods:The expression of Fra-1 was investigated by immunohistochemistry in neoplastic breast diseases ranging from benign fibroadenoma to very aggressive undifferentiated carcinoma.The correlations of Fra-1 expression with other indicators of breast carcinoma prognosis (ER,PR and ErbB2 receptors) were analyzed.Results:All neoplastic breast tissues,either benign or malignant breast tissues,were nuclear immunoreactive for Fra-1-recognizing antibody.In 85% of benign tumors (17/20),the immunoreactive for Fra-1-recognizing antibody as exclusively restricted to the nuclei.In three cases (3/20,15%),focal unequivocal cytoplasmic staining was also exhibited.Strong positive nuclear staining for Fra-1 was easily seen in all types of breast carcinomas.However the nuclear/cytoplasmic concomitant immunoreactivity was observed in all types of breast carcinomas.A clear shift in Fra-1 immunoreactivity,from an exclusively nuclear to a simultaneous nuclear and cytoplasmic localization was noticed in 90.2% (37/41) of breast carcinomas.No inverse relationship between Fra-1 and ER and PR protein levels was noticed in malignant tumors.The relative expression level of Fra-1 was not correlated with the expression of ErbB2.Conclusion:The overall expression,pattern and intensity of Fra-1 proteins were correlated with breast oncogenesis.Overexpression of Fra-1,leading to a persistent high cytoplasmic accumulation,may play a role in the process of breast carcinogenesis. | Yuhua Song Jing Wang Xiaoyun Yu Santai Song Zefei Jiang | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，6： | 0 |
| 13 | Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China显示文摘In this study,we aimed to explore the safety and vaccination coverage data of Chinese patients with breast cancer receiving coronavirus disease 2019(COVID-19)vaccination.The patients were recruited from 41 hospitals across 20 Chinese provinces.The vaccination coverage was approximately 22.4%,and the frequency of total adverse events was 13.3%after the first dose and 9.9%after the second dose.The most frequent adverse reaction within 14 days of the first dose was local pain(5.7%).Unvaccinated patients were very likely to reject the vaccine rather than be hesitant in patients with old age(odds ratio[OR],1.238;95%confidence interval[CI],1.101-1.391),chronic disease history(OR,1.189;95%CI,1.057-1.337),and cancer relapse(OR,1.398;95%CI,1.233-1.585).Of the unvaccinated patients with breast cancer,54.1%opted to receive COVID-19 vaccines if more data were available.Considering the safety but low vaccination coverage for breast cancer,increased positive attitudes and acceptance toward COVID-19 vaccines are important. | Shaohua Zhang Jianbin Li Ruonan Xu Qianjun Chen Gang Sun Ying Lin Feng Jin Xinlan Liu Zhimin Fan Yiding Chen Yali Cao Xinzheng Li Jianyun Nie Guiying Xu Xiaojia Wang Yuee Teng Tao Sun Hong Liu Jing Luo Cuizhi Geng Man Li Ting Luo Yinhua Liu Fu-Sheng Wang Zefei Jiang | 2023 | Infectious Diseases & Immunity2023，3，3： | 0 |
| 14 | 乳腺癌合并肾功能不全患者的治疗策略(英文)显示文摘Objective:The aim of this study was to investigate renal insufficiency in patients with chemotherapy.Methods:Prescribing chemotherapy in a regular hemodialysis patient with renal failure,and monitoring of serum drug concentrations to determine its safety and effectiveness.Results:Chemotherapy assessment efficiency:SD(better),hemodialysis did not affect THP treatment,their safety was guaranteed.Conclusion:The chemotherapy of renal dysfunction is not an absolute contraindication to fully assess the patient's adverse effects and tolerability,the reasonable arrangements for hemodialysis and the timing of administration can be safe and effective chemotherapy. | Meng Du Hengyan Qu Yue Wang Shikai WU Zefei Jiang | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，10： | 0 |
| 15 | Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer:A pragmatic,multicenter,and prospective clinical trial in China显示文摘Objective:This post-approval safety study assessed the efficacy and safety of exemestane after 2-3 years of tamoxifen treatment among postmenopausal women with estrogen receptor-positive(ER+)early breast cancer in China.Methods:Enrolled patients had received 2-3 years of tamoxifen and were then switched to exemestane for completion of 5 consecutive years of adjuvant endocrine therapy.The primary endpoint was the time from enrollment to the first occurrence of locoregional/distant recurrence of the primary breast cancer,appearance of a second primary or contralateral breast cancer,or death due to any cause.Other endpoints included the proportion of patients experiencing each event,incidence rate per annum,relationships between human epidermal growth factor receptor 2 status and time to event,and relationship between disease history variables and time to event.Results:Overall,558 patients were included in the full analysis set:397(71.1%)completed the study,20experienced an event,and 141 discontinued[47 owing to an adverse event(AE);37 no longer willing to participate].Median duration of treatment was 29.5(range,0.1-57.7)months.Median time to event was not reached.Eventfree survival probability at 36 months was 91.4%(95%CI,87.7%-95.1%).The event incidence over the total exposure time of exemestane therapy was 3.5 events/100 person-years(20/565).Multivariate analysis showed an association between tumor,lymph node,and metastasis stage at initial diagnosis and time to event[hazard ratio:1.532(95%CI,1.129-2.080);P=0.006].Most AEs were grade 1 or 2 in severity,with arthralgia(7.7%)being the most common treatment-related AE.Conclusions:This study supports the efficacy and safety of exemestane in postmenopausal Chinese women with ER+breast cancer previously treated with adjuvant tamoxifen for 2-3 years.No new safety signals were identified in the Chinese population. | Binghe Xu Huiping Li Zefei Jiang Lin Gu Jinhai Tang Hui Xie Yueyin Pan Yunjiang Liu Shude Cui Xiaojia Wang Li Cai Yiqiong Zhang Huadong Zhao Zhimin Shao | 2022 | Chinese Journal of Cancer Research2022，34，6： | 0 |
| 16 | Survey on Changes in the Willingness to Receive the COVID-19 Vaccine Among Patients with Breast Cancer in the Postpandemic Era显示文摘This study aimed to investigate the status of and changes in the vaccination willingness of patients with breast cancer to increase the coronavirus disease 2019(COVID-19)vaccination rate among these patients.The first survey included patients fromthe FifthMedical Center of the PLA GeneralHospitalwho participated in the Society of ClinicalOncology Breast Cancer CommitteeNCP-02 study conducted from September 16 to December 31,2021.The second survey was conducted from December 9 to December 26,2022,for those who had not received vaccines previously.In total,266 patients completed two questionnaires.A total of 143 patients(53.8%)changed their willingness to receive the vaccination.Among them,45,who were initially unwilling to be vaccinated,changed their stance to become hesitant and 15 changed to become willing.Among those with hesitant attitudes toward vaccines,45 changed their stance to become willing,and 28 changed to become unwilling;10 patients with willing attitudes toward vaccines changed to become hesitant.Those who received surgery(odds ratio(OR),4.24;95%confidence interval(CI),1.45–12.42;P=0.01)andwho lived with older adults or children(OR,2.03;95%CI,1.13–3.62;P=0.02)were more likely to change their attitudes toward COVID-19 vaccines.This finding suggested that patients with breast cancer were cautious about receiving the COVID-19 vaccine.Multiple methods should be used to promote vaccination and reduce vaccine hesitancy. | Lixiao Bai Jianbin Li Ailing Yang Cuicui Ding Jiayi Li Yan Wang Liangying Li Shaohua Zhang Zefei Jiang | 2023 | Infectious Diseases & Immunity2023，3，4： | 0 |
| 17 | CACA Guidelines for Holistic Integrative Management of Breast Cancer显示文摘Purpose:Breast cancer is now the most common malignant tumor worldwide.About one-fourth of female cancer patients all over the world sufer from breast cancer.And about one in six female cancer deaths worldwide is caused by breast cancer.In terms of absolute numbers of cases and deaths,China ranks frst in the world.The CACA Guidelines for Holistic Integrative Management of Breast Cancer were edited to help improve the diagnosis and comprehensive treatment in China.Methods:The Grading of Recommendations Assessment,Development and Evaluation(GRADE)was used to classify evidence and consensus.Results:The CACA Guidelines for Holistic Integrative Management of Breast Cancer include the epidemiology of breast cancer,breast cancer screening,breast cancer diagnosis,early breast cancer treatment,advanced breast cancer treatment,follow-up,rehabilitation,and traditional Chinese medicine treatment of breast cancer patients.Conclusion:We to standardize the diagnosis and treatment of breast cancer in China through the formulation of the CACA Guidelines. | Jiong Wu Daiming Fan Zhimin Shao Binghe Xu Guosheng Ren Zefei Jiang Yongsheng Wang Feng Jin Jin Zhang Qingyuan Zhang Fei Ma Jinli Ma Zhonghua Wang Shusen Wang Xiaojia Wang Shu Wang Haibo Wang Tao Wang Xiang Wang Jing Wang Jia Wang Biyun Wang Li Fu Hongyuan Li Yehui Shi Lu Gan Yunjiang Liu Jian Liu Zhenzhen Liu Qiang Liu Qiang Sun Wenwu Cheng Keda Yu Zhongsheng Tong Xinhong Wu Chuangui Song Jianguo Zhang Jian Zhang Junjie Li Bin Li Man Li Huiping Li Wentao Yang Hongjian Yang Benlong Yang Hong Bu Juping Shen Zhenzhou Shen Yiding Chen Ceshi Chen Da Pang Zhimin Fan Ying Zheng Xiaoli Yu Guangyu Liu Xichun Hu Yiqun Ling Jinhai Tang Yongmei Yin Cuizhi Geng Peng Yuan Yajia Gu Cai Chang Xuchen Cao Yuan Sheng Yuanxi Huang Jian Huang Weijun Peng Xiaohua Zeng Yuntao Xie Ning Liao Committee of Breast Cancer Society,Chinese Anti-Cancer Association | 2022 | Holistic Integrative Oncology2022，1，1： | 0 |
| 18 | Hot issues in triple-negative breast cancer显示文摘Triple-negative breast cancer(TNBC)is an aggressive disease with a poor prognosis.Several clinical trials have demonstrated future prospects for patients with TNBC based on improved long-term survival;however,there are still TNBC challenges,such as molecular classification and treatment optimization.Invited by Cancer Biology&Medicine,we would like to discuss four hot topics in TNBC and suggest some potential solutions(Figure 1). | Xiaopeng Hao Zefei Jiang | 2023 | Cancer Biology & Medicine2023，20，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员